Minimally invasive endovascular and hybrid surgery is playing an increasingly important role in the treatment of cardiovascular disease. Thematic scientific conferences help to promote and implement high technology in endovascular practice.
February 2024 was marked by a major event for Russian healthcare – the 15th Annual International Conference on Hybrid Technologies in the Treatment of Cardiovascular Diseases. The event traditionally takes place in Moscow at the Chazov National Medical Research Centre of Cardiology. The event brought together top specialists from Russia as well as from near and far abroad — Belarus, China, Serbia, India, Hungary, Colombia, Pakistan, Great Britain, Italy, France, Germany.
The plenary session was opened by Professor Alain Cribier from France, who performed the world's first transcatheter aortic valve implantation (TAVI). He reported on the outlook for the development of transcatheter technology. The comprehensive conference programme covered the latest issues in endovascular and hybrid interventions for diseases of the aorta and its branches, as well as innovative imaging techniques in cardiovascular surgery. The audience was able to see the latest techniques in the treatment of cardiovascular disease in real time through live surgical demonstrations.
President of the Russian Federation Vladimir Putin addressed a letter of welcome to the guests and organisers of the International Conference, which undoubtedly underlined the high and significant status of the event. The letter wishing the participants success was read by Sergey Boitsov, Academician of the Russian Academy of Sciences.
The Almazov Centre was represented by a team of researchers from the Research Department of Vascular and Interventional Surgery headed by Dr. Mikhail Chernyavsky.
Researcher Almaz Vanyurkin spoke about the key issues of hybrid surgery in the era of endovascular technology development in the treatment of aortic arch disease. In his presentation on Leriche syndrome, he highlighted the latest technologies used at the Almazov Centre and explained important aspects of the treatment of this disease.
Researcher Artem Gorbatykh presented the Almazov Centre's experience with transcatheter pulmonary artery valve replacement in young patients.
Overall, the conference provided a platform to unite and share invaluable experience and knowledge between experts and participants to facilitate the introduction of the latest technologies in modern surgery into clinical practice.